Clinical trials: Single Dose
Acute Myeloid Leukemia With FLT3/ITD Mutation
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg.
- Trial name
- XY0206-CQT (NCT07162116)
- Testing
- XY0206, Moxifloxacin (400 mg)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Hepatitis C
TD-6450 SAD and MAD in Healthy Subjects
This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.
- Trial name
- NCT02022306
- Testing
- TD-6450
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Healthy
Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test carvedilol formulation (TEVA Pharmaceuticals USA) to and equivalent oral dose of the commercially…
- Trial name
- NCT00834795
- Testing
- Carvedilol 25 mg tablets, COREG® 25 mg tablets
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Lung Cancer (Locally Advanced or Metastatic)
Pemefolacianine for IMI of Lung Cancer
The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of Pemefolacianine for Injection, a novel fluorescence imaging agent developed by Nanjing Nuoyuan Medical Devices Co., Ltd…
- Trial name
- NCT07772895
- Testing
- Pemefolacianine Cohort 1 in Part A, Pemefolacianin Cohort 2 in Part B
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sunil Singhal
Healthy Participants Study, Rheumatoid Arthritis
A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.
- Conditions
- Healthy Participants Study, Rheumatoid Arthritis, Sjogren's Syndrome
- Trial name
- NCT07712939
- Testing
- CND319
- Where
- Australia
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Candid Therapeutics
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Healthy
Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy Volunteers
Metformin Glycinate is a novel biguanide compound developed as a potential candidate for the treatment of type 2 diabetes. Metformin Glycinate was found to improve metabolic control in naive patients with type 2 diabetes.
- Trial name
- NTC00940472 (NCT01560481)
- Testing
- Step A: metformin glycinate 620 mg single dose, Step A: metformin glycinate 1240 mg single dose, Step A: metformin glycinate 2480 mg single dose
- Where
- Spain
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Asthma
AMG 761 in Adults With Asthma
The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.
- Trial name
- NCT01514981
- Testing
- AMG 761
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Amgen
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Daptomycin is a new antimicrobial agent which has activity against resistant Gram positive cocci including MRSA. The phase 3 clinical trials for skin and soft tissue infections (SSTI) with Staphylococci and Streptococci have…
- Conditions
- Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
- Trial name
- NCT00261807
- Testing
- Daptomycin 6mg/kg/day
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Healthy
A PET Study With ORM-12741
The purpose of the study is to evaluate the effect of ORM-12741 on receptor occupancy by positron emission tomography with different doses and plasma concentrations. The pharmacokinetic profile and safety will also be evaluated.
- Trial name
- NCT00829907
- Testing
- ORM-12741
- Where
- Finland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Dementia, Frontotemporal
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants
This is a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of VES001 in a two part followed by a…
- Trial name
- SORT-IN-1 (NCT06226064)
- Testing
- VES001
- Where
- Netherlands
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Vesper Biotechnologies ApS
Advanced Hepatocellular Carcinoma
Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma
A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma
- Trial name
- NCT04973098
- Testing
- CT0181 Cells
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Peking University
Substance Dependence
Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00437632
- Testing
- GSK598809, Caffeine
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes
This trial is conducted to evaluate the safety of a study drug given by injection under the skin to healthy participants and participants with type 2 diabetes.
- Trial name
- NCT02942914
- Testing
- LY3209590, Insulin Glargine
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers
Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 655064 after single rising doses in healthy Asian male volunteers.
- Trial name
- NCT01917916
- Testing
- BI 655064
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects
This is a phase 1, non-randomized, fixed sequence, 3-period, drug-drug interaction study to assess the pharmacokinetics (PK) of AZD7986 in healthy subjects when administered alone and in combination with multiple doses of…
- Trial name
- NCT02653872
- Testing
- AZD7986, Verapamil, Itraconazole
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
The purpose of this study is to investigate the effect of Atorvastatin on the pharmacokinetic properties of Telmisartan/S-amlodipine
- Trial name
- CKD-345 DDI (NCT01842230)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, Telmisartan 80mg and S-amlodipine 5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
A Clinical Trial to Evaluate the Food Effect of CKD-379
A clinical trial to evaluate the food effect of CKD-379
- Trial name
- CKD-379 (NCT06652971)
- Testing
- CKD-379
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteer
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults
The purpose of this study is to assess the bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of different formulations of a CGRP receptor antagonist in…
- Trial name
- NCT07261371
- Testing
- Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Cancer, Ovarian Cancer
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients
Bioequivalence study is proposed to be carried out on patients of breast cancer/ ovarian cancer, who are administrated for Doxorubicin Hydrochloride Liposomal Injection Lipodox® or Caelyx® in a dose of 50 mg/m2.
- Trial name
- NCT05273944
- Testing
- Doxorubicin Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.